MCK logo

McKesson Corporation Stock Price

NYSE:MCK Community·US$91.4b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 98 Fair Values set on narratives written by author

MCK Share Price Performance

US$760.57
34.17 (4.70%)
US$951.73
Fair Value
US$760.57
34.17 (4.70%)
20.1% undervalued intrinsic discount
US$951.73
Fair Value
Price US$760.57
AnalystConsensusTarget US$951.73

MCK Community Narratives

·
Fair Value US$951.73 20.1% undervalued intrinsic discount

Analysts Boost McKesson Outlook Amid Strong Growth Guidance and Recent Valuation Adjustments

0users have liked this narrative
0users have commented on this narrative
49users have followed this narrative

Trending Discussion

Updated Narratives

MCK logo

MCK: Biosimilar Co Manufacturing Will Shape Future Healthcare Safe Haven Appeal

Fair Value: US$951.73 20.1% undervalued intrinsic discount
49 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Solid track record and good value.

1 Risk
5 Rewards

McKesson Corporation Key Details

US$403.4b

Revenue

US$388.9b

Cost of Revenue

US$14.5b

Gross Profit

US$9.8b

Other Expenses

US$4.8b

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
39.62
3.60%
1.18%
-780.5%
View Full Analysis

About MCK

Founded
1833
Employees
42300
CEO
Brian Tyler
WebsiteView website
www.mckesson.com

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Recent MCK News & Updates

Narrative Update May 13

MCK: Biosimilar Co Manufacturing Will Shape Future Healthcare Safe Haven Appeal

Analysts have trimmed the McKesson fair value estimate by about $39 to $951.73. This reflects updated views on slightly higher discount rates, a more moderate revenue growth outlook, a small shift in profit margin assumptions, and a lower future P/E multiple after a mix of recent price target increases and cuts across the Street.
Analysis Article May 11

McKesson Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

McKesson Corporation ( NYSE:MCK ) shareholders are probably feeling a little disappointed, since its shares fell 8.9...

Recent updates

No updates